PLoS ONE (Jan 2021)

Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.

  • Calvin Q Pan,
  • Ting-Tsung Chang,
  • Si Hyun Bae,
  • Maurizia Brunetto,
  • Wai-Kay Seto,
  • Carla S Coffin,
  • Susanna K Tan,
  • Shuyuan Mo,
  • John F Flaherty,
  • Anuj Gaggar,
  • Mindie H Nguyen,
  • Mustafa Kemal Çelen,
  • Alexander Thompson,
  • Edward J Gane

DOI
https://doi.org/10.1371/journal.pone.0251552
Journal volume & issue
Vol. 16, no. 5
p. e0251552

Abstract

Read online

Background/purposeUse of tenofovir disoproxil fumarate (TDF) improves patient outcomes in preventing mother-to-child transmission (pMTCT) of the hepatitis B virus (HBV) in mothers with chronic HBV and high viral loads. Given the lack of data for tenofovir alafenamide (TAF) in pMTCT, rates of early viral suppression with TAF and TDF were evaluated in women of childbearing potential (WOCBP) participating in 2 randomized, double-blind, Phase 3 studies in chronic HBV.MethodsIn a patient subset meeting WOCBP criteria and with baseline HBV DNA >200,000 IU/mL, rates of viral suppression with TAF or TDF in achieving the target of HBV DNA ResultsIn 275 of 1298 (21%) patients meeting WOCBP criteria with high viral load, 93% and 96% had HBV DNA ConclusionsIn WOCBP with high VL, no differences were found between TAF and TDF in reducing HBV DNA to levels associated with lower transmission risk. These data support ongoing studies of TAF for pMTCT.